Abstract
Alzheimer's Disease (AD) is a multifactorial and fatal neurodegenerative disorder affecting around 35 million people worldwide, which is characterized by decline of cholinergic function, deregulation of amyloid beta (Aβ) oligomers formation and Aβ fibril deposition. Multi-Target- Directed Ligands (MTDLs) have emerged as an original strategy for developing new therapeutic agents on AD. Multicomponent Reactions (MCRs) are a useful alternative to sequential multistep syntheses, allowing scaffold diversity and a rapid and easy access to biologically relevant compounds. The biological diversity of MCRs is very rich providing great possibilities for researchers interested in bioactive small molecular weight compounds. Since the MTDL strategy has been used to develop compounds endowed with the capacity to interact with different targets, versatile compound libraries may be obtained by MCRs according to the well established features of each target. Thus, either MTDLs or monotarget compounds have been developed by MCRs to address different factors implicated in AD. This work focuses on antioxidants, calcium channel modulators, both AChE and BuChE inhibitors, BACE1 inhibitors, and modulators of the nuclear factor (erythroid-derived 2)-like 2. First, we discuss the Biginelli reaction and its use for developing new interesting compounds for AD, followed by the contribution of Ugi reaction and, finally, the interest of other MCRs in the same topic.
Keywords: Alzheimer's Disease, Multicomponent reactions, Multitargeted compounds, Multi-target-Directed Ligands, Ugi reaction, Biginelli reaction.
Current Topics in Medicinal Chemistry
Title:Multicomponent Reactions for Multitargeted Compounds for Alzheimer`s Disease
Volume: 17 Issue: 31
Author(s): Lhassane Ismaili*Maria do Carmo Carreiras
Affiliation:
- Neurosciences Integratives et Cliniques EA 481, Laboratoire de Chimie Organique et Therapeutique, UFR SMP, 19 rue Ambroise Pare, Universite Bourgogne Franche-Comte, F25000 Besancon,France
Keywords: Alzheimer's Disease, Multicomponent reactions, Multitargeted compounds, Multi-target-Directed Ligands, Ugi reaction, Biginelli reaction.
Abstract: Alzheimer's Disease (AD) is a multifactorial and fatal neurodegenerative disorder affecting around 35 million people worldwide, which is characterized by decline of cholinergic function, deregulation of amyloid beta (Aβ) oligomers formation and Aβ fibril deposition. Multi-Target- Directed Ligands (MTDLs) have emerged as an original strategy for developing new therapeutic agents on AD. Multicomponent Reactions (MCRs) are a useful alternative to sequential multistep syntheses, allowing scaffold diversity and a rapid and easy access to biologically relevant compounds. The biological diversity of MCRs is very rich providing great possibilities for researchers interested in bioactive small molecular weight compounds. Since the MTDL strategy has been used to develop compounds endowed with the capacity to interact with different targets, versatile compound libraries may be obtained by MCRs according to the well established features of each target. Thus, either MTDLs or monotarget compounds have been developed by MCRs to address different factors implicated in AD. This work focuses on antioxidants, calcium channel modulators, both AChE and BuChE inhibitors, BACE1 inhibitors, and modulators of the nuclear factor (erythroid-derived 2)-like 2. First, we discuss the Biginelli reaction and its use for developing new interesting compounds for AD, followed by the contribution of Ugi reaction and, finally, the interest of other MCRs in the same topic.
Export Options
About this article
Cite this article as:
Ismaili Lhassane*, do Carmo Carreiras Maria , Multicomponent Reactions for Multitargeted Compounds for Alzheimer`s Disease, Current Topics in Medicinal Chemistry 2017; 17 (31) . https://dx.doi.org/10.2174/1568026618666180112155424
DOI https://dx.doi.org/10.2174/1568026618666180112155424 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Linking Alzheimer’s Disease and Type 2 Diabetes Mellitus via Aberrant Insulin Signaling and Inflammation
CNS & Neurological Disorders - Drug Targets Neurodegeneration in the Pathogenesis of Diabetic Retinopathy: Molecular Mechanisms and Therapeutic Implications
Current Medicinal Chemistry NRF2-Dependent Glutamate-L-Cysteine Ligase Catalytic Subunit Expression Mediates Insulin Protection Against Hyperglycemia-Induced Brain Endothelial Cell Apoptosis
Current Neurovascular Research Meet the Editorial Board Member
Current Neuropharmacology Lipid Raft Alterations in Aged-Associated Neuropathologies
Current Alzheimer Research Electromagnetic Field in Alzheimer’s Disease: A Literature Review of Recent Preclinical and Clinical Studies
Current Alzheimer Research Therapeutic Strategies for the Treatment of Spinal Muscular Atrophy (SMA) Disease
Current Genomics Involvement of Immune Response in the Pathogenesis of Amyotrophic Lateral Sclerosis: A Therapeutic Opportunity?
CNS & Neurological Disorders - Drug Targets Role of Secretory Phospholipase A2 in CNS Inflammation: Implications in Traumatic Spinal Cord Injury
CNS & Neurological Disorders - Drug Targets Probing Multidrug Resistance P-glycoprotein Transporter Activity with SPECT Radiopharmaceuticals
Current Topics in Medicinal Chemistry Discovery of Novel CK2 Leads by Cross-Docking Based Virtual Screening
Medicinal Chemistry Neuroprotective Potential of Adenyl Cyclase/cAMP/CREB and Mitochondrial CoQ10 Activator in Amyotrophic Lateral Sclerosis Rats
Current Bioactive Compounds Inhibition of Opioid Receptor Mediated G-Protein Activity After Chronic Administration of Kynurenic Acid and its Derivative without Direct Binding to Opioid Receptors
CNS & Neurological Disorders - Drug Targets The Emerging Role of Metabotropic Glutamate Receptors in the Pathophysiology of Chronic Stress-Related Disorders
Current Neuropharmacology Elicitation of Dopaminergic Features of Parkinson’s Disease in C. elegans by Monocrotophos, an Organophosphorous Insecticide
CNS & Neurological Disorders - Drug Targets Emerging Perspectives on DNA Double-strand Breaks in Neurodegenerative Diseases
Current Neuropharmacology Tissue Plasminogen Activator Prevents Restoration of Tight Junction Proteins Through Upregulation of Angiopoietin-2
Current Neurovascular Research SUBJECT INDEX TO VOLUME 1
Current Genomics The Effects of Creatine Supplementation and Physical Exercise on Traumatic Brain Injury
Mini-Reviews in Medicinal Chemistry Allosteric Modulation of Muscarinic Acetylcholine Receptors
Current Neuropharmacology